Treatment of HTLV-I-associated myelopathy/tropical spastic paraparesis: toward rational targeted therapy.
The treatment of HAM/TSP is a challenge. No agent has shown to significantly modify the long-term disability associated with HAM/TSP. Advances in our understanding of the pathogenesis of HAM/TSP have led to the identification of several biomarkers and therapeutic targets. Clinical trials in HAM/TSP continue to be opportunities for further qualification and refinement of biomarkers and therapeutic targets. The validation of HAM/TSP relevant biomarkers and the identification of new targets remain key challenges in the development of effective targeted therapy in HAM/TSP.
Oh
Unsong
U
Viral Immunology Section, Neuroimmunology Branch, National Institute of Neurological Diseases and Stroke, 10 Center Drive, Bldg 10 Rm 5C103, Bethesda, MD 20892, USA.
Jacobson
Steven
S
D001253:Astrocytes / Q000473:pathology / Q000821:virology; D001921:Brain / Q000473:pathology / Q000821:virology; D003937:Diagnosis, Differential; D018450:Disease Progression; D004358:Drug Therapy / Q000379:methods*; D006801:Humans; D009410:Nerve Degeneration / Q000473:pathology; D015493:Paraparesis, Tropical Spastic / Q000175:diagnosis* / Q000188:drug therapy* / Q000635:transmission; D016133:Polymerase Chain Reaction; D012307:Risk Factors; D013116:Spinal Cord / Q000473:pathology